HSF1 and prostate carcinoma: A notable direct inhibitor of HSF1, DTHIB (Direct Targeted HSF1 InhiBitor), achieves its effect by accelerating nuclear HSF1 degradation and has shown strong efficacy in multiple models of resistant prostate cancer [156].